By employing a mouse line expressing human instead of endogenous murine Plexin-B1, we demonstrate that this anti–Plexin-B1 antibody exhibits therapeutic efficacy in preclinical models of osteoporosis and MS in vivo. This evidence concerns the gene PLXNB1 and osteoporosis.